TEPI Patch® technology supports the development of a new generation of transdermal drug delivery patches, including for drugs where patch delivery was previously not viable and patches for sustained delivery of drugs over a prolonged period.
Transdermal patches offer an alternative route of administration for drugs that are not ideally suited to oral administration, for reasons such as first pass metabolism, gastrointestinal toxicity or low bioavailability, and better dose control and less frequent dosing than gels or creams.
Medherant’s TEPI Patch® is a new transdermal drug delivery system based on a novel adhesive which confers superior properties on the products.
Benefits include:
- Thin, flexible, comfortable and moisture-resistant with good adhesion
- No dark residue around the patch (‘cold flow’) or on the skin after removal
- Better patient compliance due to simple, convenient application and painless removal
- A wide range of drugs can be formulated as a TEPI Patch, offering a new opportunity for product line extensions
- Can potentially improve the pharmacokinetics and safety profile of a drug
- Permeation enhancers and other excipients can be included in the formulation to tailor the rate of drug release
Our lead product is testosterone TEPI Patch for women, which is currently in clinical development.
Medherant has also entered into a development collaboration with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine. Medherant is leading the programme through to clinical proof of concept.